Scalper1 News
Zafgen (ZFGN), a developer of treatments for severe obesity and hunger-related disorders, rose 22% on its IPO debut Thursday. Zafgen raised $96 million by offering 6 million shares at 16, the high end of its range. Another biotech with an initial public offering Thursday was Ardelyx (ARDX), which is developing therapies for late-stage kidney disease. It raised $60 million by offering 4.3 million shares at 14, the midpoint of its range. The stock Scalper1 News
Scalper1 News